Joinn Laboratories(China)Co (603127) - Net Assets
Based on the latest financial reports, Joinn Laboratories(China)Co (603127) has net assets worth CN¥8.56 Billion CNY (≈ $1.25 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.04 Billion ≈ $1.47 Billion USD) and total liabilities (CN¥1.48 Billion ≈ $216.53 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Joinn Laboratories(China)Co total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.56 Billion |
| % of Total Assets | 85.26% |
| Annual Growth Rate | 40.6% |
| 5-Year Change | 16.53% |
| 10-Year Change | 3099.78% |
| Growth Volatility | 124.78 |
Joinn Laboratories(China)Co - Net Assets Trend (2012–2025)
This chart illustrates how Joinn Laboratories(China)Co's net assets have evolved over time, based on quarterly financial data. Check how tangible is Joinn Laboratories(China)Co's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Joinn Laboratories(China)Co (2012–2025)
The table below shows the annual net assets of Joinn Laboratories(China)Co from 2012 to 2025. For live valuation and market cap data, see Joinn Laboratories(China)Co stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.33 Billion ≈ $1.22 Billion |
+3.05% |
| 2024-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
-2.44% |
| 2023-12-31 | CN¥8.28 Billion ≈ $1.21 Billion |
+1.10% |
| 2022-12-31 | CN¥8.19 Billion ≈ $1.20 Billion |
+14.65% |
| 2021-12-31 | CN¥7.14 Billion ≈ $1.05 Billion |
+483.62% |
| 2020-12-31 | CN¥1.22 Billion ≈ $179.13 Million |
+47.98% |
| 2019-12-31 | CN¥827.26 Million ≈ $121.05 Million |
+26.97% |
| 2018-12-31 | CN¥651.52 Million ≈ $95.34 Million |
+16.80% |
| 2017-12-31 | CN¥557.79 Million ≈ $81.62 Million |
+114.38% |
| 2016-12-31 | CN¥260.18 Million ≈ $38.07 Million |
+24.88% |
| 2015-12-31 | CN¥208.35 Million ≈ $30.49 Million |
+30.98% |
| 2014-12-31 | CN¥159.07 Million ≈ $23.28 Million |
+30.51% |
| 2013-12-31 | CN¥121.89 Million ≈ $17.84 Million |
+22.78% |
| 2012-12-31 | CN¥99.27 Million ≈ $14.53 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Joinn Laboratories(China)Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 239337437170.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.37 Billion | 28.47% |
| Other Components | CN¥5.95 Billion | 71.53% |
| Total Equity | CN¥8.32 Billion | 100.00% |
Joinn Laboratories(China)Co Competitors by Market Cap
The table below lists competitors of Joinn Laboratories(China)Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kilroy Realty Corp
NYSE:KRC
|
$4.53 Billion |
|
Fujian Funeng Co Ltd
SHG:600483
|
$4.53 Billion |
|
AAC TECHNOLOG.HLDG.ADR/
F:A2X
|
$4.53 Billion |
|
Hubei Energy Group Co Ltd
SHE:000883
|
$4.53 Billion |
|
CSW Industrials, Inc.
NYSE:CSW
|
$4.53 Billion |
|
Kulicke and Soffa Industries Inc
F:KU1
|
$4.53 Billion |
|
KURITA WTR IND.UNSP.ADR 2
F:KWI0
|
$4.52 Billion |
|
Fulton Financial Corporation
NASDAQ:FULT
|
$4.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Joinn Laboratories(China)Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,078,818,586 to 8,324,980,015, a change of 246,161,429 (3.0%).
- Net income of 297,841,048 contributed positively to equity growth.
- Dividend payments of 22,385,229 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥297.84 Million | +3.58% |
| Dividends Paid | CN¥22.39 Million | -0.27% |
| Other Changes | CN¥-29.29 Million | -0.35% |
| Total Change | CN¥- | 3.05% |
Book Value vs Market Value Analysis
This analysis compares Joinn Laboratories(China)Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 224.13x to 4.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.22 | CN¥49.12 | x |
| 2013-12-31 | CN¥0.26 | CN¥49.12 | x |
| 2014-12-31 | CN¥0.34 | CN¥49.12 | x |
| 2015-12-31 | CN¥0.45 | CN¥49.12 | x |
| 2016-12-31 | CN¥0.56 | CN¥49.12 | x |
| 2017-12-31 | CN¥1.08 | CN¥49.12 | x |
| 2018-12-31 | CN¥1.05 | CN¥49.12 | x |
| 2019-12-31 | CN¥1.34 | CN¥49.12 | x |
| 2020-12-31 | CN¥1.97 | CN¥49.12 | x |
| 2021-12-31 | CN¥9.80 | CN¥49.12 | x |
| 2022-12-31 | CN¥10.91 | CN¥49.12 | x |
| 2023-12-31 | CN¥11.05 | CN¥49.12 | x |
| 2024-12-31 | CN¥10.91 | CN¥49.12 | x |
| 2025-12-31 | CN¥11.11 | CN¥49.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Joinn Laboratories(China)Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.97%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.16x
- Recent ROE (3.58%) is below the historical average (15.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 9.70% | 9.88% | 0.26x | 3.83x | CN¥-301.67K |
| 2013 | 18.34% | 15.50% | 0.38x | 3.13x | CN¥10.13 Million |
| 2014 | 30.87% | 26.51% | 0.41x | 2.85x | CN¥33.12 Million |
| 2015 | 23.64% | 23.80% | 0.43x | 2.32x | CN¥28.37 Million |
| 2016 | 19.89% | 21.38% | 0.40x | 2.30x | CN¥25.71 Million |
| 2017 | 13.71% | 25.37% | 0.32x | 1.69x | CN¥20.70 Million |
| 2018 | 16.63% | 26.50% | 0.36x | 1.75x | CN¥43.21 Million |
| 2019 | 22.60% | 29.21% | 0.45x | 1.72x | CN¥104.12 Million |
| 2020 | 25.72% | 29.28% | 0.51x | 1.72x | CN¥192.52 Million |
| 2021 | 7.81% | 36.76% | 0.18x | 1.20x | CN¥-156.16 Million |
| 2022 | 13.13% | 47.37% | 0.22x | 1.27x | CN¥255.89 Million |
| 2023 | 4.79% | 16.71% | 0.24x | 1.21x | CN¥-430.94 Million |
| 2024 | 0.92% | 3.67% | 0.21x | 1.16x | CN¥-733.81 Million |
| 2025 | 3.58% | 17.97% | 0.17x | 1.16x | CN¥-534.66 Million |
Industry Comparison
This section compares Joinn Laboratories(China)Co's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,093,723,611
- Average return on equity (ROE) among peers: 11.61%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Joinn Laboratories(China)Co (603127) | CN¥8.56 Billion | 9.70% | 0.17x | $4.53 Billion |
| Berry Genomics Co Ltd (000710) | $130.03 Million | 5.29% | 2.43x | $397.81 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $589.81 Million | 14.60% | 0.38x | $1.65 Billion |
| Hangzhou Tigermed Consulting (300347) | $44.26 Million | 17.63% | 0.52x | $5.42 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.97 Billion | 16.83% | 0.09x | $972.92 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.71 Billion | 9.48% | 0.29x | $469.59 Million |
| Maccura Biotechnology Co Ltd (300463) | $2.00 Billion | 12.55% | 0.19x | $780.41 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $3.48 Billion | 24.52% | 0.22x | $479.64 Million |
| BGI Genomics Co Ltd (300676) | $8.61 Billion | -7.16% | 0.36x | $2.25 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $1.02 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.10 Billion | 0.58% | 0.20x | $496.41 Million |
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more